Serotonergic system as a therapeutic target in multiple sclerosis

Sviridova A.A.; Mel'nikov M.V.; Belousova O.O.; Rogovsky V.S.; Pashchenkov M.V.; Boĭko A.N.

doi:https://doi.org/10.17116/jnevro20191192264

References:

Martin R, Sospedra M, Rosito M, Engelhardt B. Current multiple sclerosis treatments have improved our understanding of MS autoimmunopathogenesis. Eur J Immunol. 2016;46(9):2078-2090. https://doi.org/10.1002/eji.201646485
Artemiadis AK, Anagnostouli MC, Alexopoulos EC. Stress as a risk factor for multiple sclerosis onset or relapse: a systematic review. Neuroepidemiology. 2011;36(2):109-120. https://doi.org/10.1159/000323953
Gold SM, Heesen C. Stress and disease progression in multiple sclerosis and its animal models. Neuroimmunomodulation. 2006;13(5-6):318-326.
Mitsonis CI, Potagas C, Zervas I, Sfagos K. The effects of stressful life events on the course of multiple sclerosis: a review. Int J Neurosci. 2009;119(3):315-335. https://doi.org/10.1080/00207450802480192
Melnikov M, Rogovskii V, Boyko A, Pashenkov M. The influence of biogenic amines on Th17-mediated immune response in multiple sclerosis. Mult Scler Relat Disord. 2018;21:19-23. https://doi.org/10.1016/j.msard.2018.02.012
Melnikov MV, Pashenkov MV, Boyko AN. Psychoneuroimmunology and multiple sclerosis. Journal of Neurology and Psychiatry S.S. Korsakov. 2015;115(2-2):8-15. (In Russ.)
Wu H, Denna TH, Storkersen JN, Gerriets VA. Beyond a neurotransmitter: The role of serotonin in inflammation and immunity. Pharmacol Res. 2018;140:100-114. pii: S1043-6618(18)30301-3. https://doi.org/10.1016/j.phrs.2018.06.015
Boyko A, Melnikov M, Ghetishev R, Pashenkov M. The role of biogenic amines in regulation of interaction between immune and nervous systems in multiple sclerosis. Neuroimmunomodulation. 2016;23(4):217-223. https://doi.org/10.1159/000449167
Malinova TS, Dijkstra CD, de Vries HE. Serotonin: A mediator of the gut-brain axis in multiple sclerosis. Mult Scler. 2018;24(9):1144-1150. https://doi.org/10.1177/1352458517739975
Oleskin AV, Shenderov BA, Rogovsky VS. Role of Neurochemicals in the Interaction between the Microbiota and the Immune and the Nervous System of the Host Organism. Probiotics Antimicrob Proteins. 2017;9(1):1-20. https://doi.org/10.1007/s12602-017-9262-1
Kozhieva MKh, Melnikov MV, Rogovskiy VS, Oleskin AV, Kabilov MR, Boyko AN. Intestinal microbiota and multiple sclerosis. Journal of Neurology and Psychiatry S.S. Korsakov. 2017;117(10-2):11-19. (In Russ.)
McGinley AM, Edwards SC, Raverdeau M, Mills KH. Th17 cells, γδ T cells and their interplay in EAE and multiple sclerosis. J Autoimmun. 2018;87:97-108. pii: S0896-8411(18)30007-6. https://doi.org/10.1016/j.jaut.2018.01.001
Dubin PJ, Kolls JK. Th17 cytokines and mucosal immunity. Immunol Rev. 2008;226:160-171. https://doi.org/10.1111/j.1600-065X.2008.00703.x
Passos, GRD, Sato DK, Becker J, Fujihara K. Th17 cells pathways in multiple sclerosis and neuromyelitis optica spectrum disorders: pathophysiological and therapeutic implications. Mediators Inflamm. 2016;2016(5314541):11. https://doi.org/10.1155/2016/5314541
El-Behi M, Ciric B, Dai H, Yan Y, Cullimore M, Safavi F, Zhang GX, Dittel BN, Rostami A. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol. 2011;12(6):568-575. https://doi.org/10.1038/ni.2031
Li YF, Zhang SX, Ma XW, Xue YL, Gao C, Li X. Levels of peripheral Th17cells and serum Th17-related cytokines in patients with multiple sclerosis: a metaanalysis. Mult Scler Relat Disord. 2017;18:20-25. https://doi.org/10.1016/j.msard
Singh RP, Hasan S, Sharma S, Nagra S, Yamaguchi DT, Wong DT, Hahn BH, Hossain A. Th17 cells in inflammation and autoimmunity. Autoimmun Rev. 2014;13(12):1174-1181. https://doi.org/10.1016/j.autrev.2014.08.019
Juszczak M, Głabinski A. Th17 cells in the pathogenesis of multiple sclerosis. Postepy Hig Med Dosw (Online). 2009;63:492-501.
Durelli L, Conti L, Clerico M, Boselli M, Contessa G, Ripellino P, Ferrero B, Eid P, Novelli F. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann Neurol. 2009;65(5):499-509.
Melnikov MV, Belousova OO, Murugin VV, Pashenkov MV, Boyko AN. The role of dopamine in modulation of Th-17 immune response in multiple sclerosis. Journal of Neuroimmunology. 2016;292:97-101. https://doi.org/10.1016/j.jneuroim.2016.01.020
Waisman A, Hauptmann J, Regen T. The role of IL-17 in CNS diseases. Acta Neuropathol. 2015;129(5):625-637. https://doi.org/10.1007/s00401-015-1402-7
Begum-Haque S, Sharma A, Kasper IR, Foureau DM, Mielcarz DW, Haque A, Kasper LH. Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2008;204(1-2):58-65. https://doi.org/10.1016/j.jneuroim.2008.07.018
Sato DK, Nakashima I, Bar-Or A, Misu T, Suzuki C, Nishiyama S, Kuroda H, Fujihara K, Aoki M. Changes in Th17 and regulatory T cells after fingolimod initiation to treat multiple sclerosis. J Neuroimmunol. 2014;268(1-2):95-98. https://doi.org/10.1016/j.jneuroim.2014.01.008
Zhao Q, Cheng W, Xi Y, Cao Z, Xu Y, Wu T, Li C, Niu X, Chen G. IFN-β regulates Th17 differentiation partly through the inhibition of osteopontin in experimental autoimmune encephalomyelitis. Mol Immunol. 2018;93:20-30. https://doi.org/10.1016/j.molimm.2017.11.002
Omenetti S, Pizarro TT. The Treg/Th17 axis: a dynamic balance regulated by the gut microbiome. Frontiers in Immunology. 2015;6:639. https://doi.org/10.3389/fimmu.2015.00639
Cosorich I, Dalla-Costa G, Sorini C, Ferrarese R, Messina MJ, Dolpady J, Radice E, Mariani A, Testoni PA, Canducci F, Comi G, Martinelli V, Falcone M. High frequency of intestinal TH17 cells correlates with microbiota alterations and disease activity in multiple sclerosis. Sci Adv. 2017;3(7): e1700492. https://doi.org/10.1126/sciadv.1700492
Jadidi-Niaragh F, Mirshafiey A. Th17 cell the new player of neuroinflammatory process in multiple sclerosis. Scand J Immunol. 2011;74(1):1-13. https://doi.org/10.1111/j.1365-3083.2011.02536.x
Esplugues E, Huber S, Gagliani N, Hauser AE, Town T, Wan YY, O’Connor W Jr, Rongvaux A, Van Rooijen N, Haberman AM, Iwakura Y, Kuchroo VK, Kolls JK, Bluestone JA, Herold KC, Flavell RA. Control of TH17 cells occurs in the small intestine. Nature. 2011;475(7357):514-518. https://doi.org/10.1038/nature10228
Stadhouders R, Lubberts E, Hendriks RW. A cellular and molecular view of T helper 17 cell plasticity in autoimmunity. J Autoimmun. 2018;87:1-15. pii: S0896-8411(17)30803-X. https://doi.org/10.1016/j.jaut.2017.12.007
Sun L, Fu J, Zhou Y. Metabolism Controls the Balance of Th17/T-Regulatory Cells. Front Immunol. 2017;8:1632. https://doi.org/10.3389/fimmu.2017.01632
Gagliani N, Amezcua Vesely MC, Iseppon A, Brockmann L, Xu H, Palm NW, de Zoete MR, Licona-Limón P, Paiva RS, Ching T, Weaver C, Zi X, Pan X, Fan R, Garmire LX, Cotton MJ, Drier Y, Bernstein B, Geginat J, Stockinger B, Esplugues E, Huber S, Flavell RA. Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature. 2015;523(7559):221-225. https://doi.org/10.1038/nature14452
Boniface K, Blumenschein WM, Brovont-Porth K, McGeachy MJ, Basham B, Desai B, Pierce R, McClanahan TK, Sadekova S, de Waal Malefyt R. Human Th17 cells comprise heterogeneous subsets including IFN-gamma-producing cells with distinct properties from the Th1 lineage. J Immunol. 2010;185(1):679-687.
Lee YK, Turner H, Maynard CL, Oliver JR, Chen D, Elson CO, Weaver CT. Late developmental plasticity in the T helper 17 lineage. Immunity. 2009;30(1):92-107.
Rogovskii VS. The linkage between inflammation and immune tolerance: interfering with inflammation in cancer. Curr Cancer Drug Targets. 2017;17(4):325-332. https://doi.org/10.2174/1568009617666170109110816
Tai Y, Wang Q, Korner H, Zhang L, Wei W (2018) Molecular Mechanisms of T Cells Activation by DCs in Autoimmune Diseases. Front Pharmacol. 2018;9:642. https://doi.org/10.3389/fphar.2018.00642
Mbongue J, Nicholas D, Firek A, Langridge W. The role of DCs in tissue-specific autoimmunity. J Immunol Res. 2014;2014(857143):17. https://doi.org/10.1155/2014/857143
Melnikov MV, Pashenkov MV, Boyko AN. Dendritic cells in multiple sclerosis. Journal of Neurology and Psychiatry S.S. Korsakov. 2017;117(2):22-30. (In Russ)
Nowatzky J, Manches O, Khan SA, Godefroy E, Bhardwaj N. Modulation of human Th17 cell responses through complement receptor 3 (CD11 b/CD18) ligation on monocyte-derived dendritic cells. J Autoimmun. 2018;92:57-66. https://doi.org/10.1016/j.jaut.2018.05.005
Pashenkov M, Huang YM, Kostulas V, Haglund M, Söderström M, Link H. Two subsets of dendritic cells are present in human cerebrospinal fluid. Brain. 2001;124(3):480-492.
Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, Castle D, Mandell JW, Lee KS, Harris TH, Kipnis J. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523(7560):337-341. https://doi.org/10.1038/nature14432
De Laere M, Berneman ZN, Cools N. To the Brain and Back: Migratory Paths of Dendritic Cells in Multiple Sclerosis. J Neuropathol Exp Neurol. 2018;77(3):178-192. https://doi.org/10.1093/jnen/nlx114
Zozulya AL, Clarkson BD, Ortler S, Fabry Z, Wiendl H. The role of DCs in CNS autoimmunity. J Mol Med (Berl). 2010;88(6):535-544. https://doi.org/10.1007/s00109-010-0607-4
Serafini B, Rosicarelli B, Magliozzi R, Stigliano E, Capello E, Mancardi GL, Aloisi F. Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cells. J Neuropathol Exp Neurol. 2006;65(2):124-141.
Longhini AL, von Glehn F, Brandão CO, de Paula RF, Pradella F, Moraes AS, Farias AS, Oliveira EC, Quispe-Cabanillas JG, Abreu CH, Damasceno A, Damasceno BP, Balashov KE, Santos LM. Plasmacytoid dendritic cells are increased in cerebrospinal fluid of untreated patients patients during multiple sclerosis relapse. J Neuroinflammation. 2011;8(1):2.
Dittel BN, Visintin I, Merchant RM, Janeway CA. Presentation of the self antigen myelin basic protein by dendritic cells leads to experimental autoimmune encephalomyelitis. J Immunol. 1999;163(1):32-39.
Ludewig B, Junt T, Hengartner H, Zinkernagel RM. Dendritic cells in autoimmune diseases. Curr Opin Immunol. 2001;13(6):657-662.
Watanabe H, Inaba M, Adachi Y, Sugiura K, Hisha H, Iguchi T, Ito T, Yasumizu R, Inaba K, Yamashita T, Ikehara S. Experimental autoimmune thyroiditis induced by thyroglobulin-pulsed dendritic cells. Autoimmunity. 1999;31(4):273-282.
Cua DJ, Sherlock J, Chen Y, Murphy CA, Joyce B, Seymour B, Lucian L, To W, Kwan S, Churakova T, Zurawski S, Wiekowski M, Lira SA, Gorman D, Kastelein RA, Sedgwick JD. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003;421(6924):744-748.
Thakker P, Leach MW, Kuang W, Benoit SE, Leonard JP, Marusic S. IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. J Immunol. 2007;178(4):2589-2598.
Vaknin-Dembinsky A, Balashov K, Weiner HL. IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J Immunol. 2006;176(12):7768-7774.
Codarri L, Gyülvészi G, Tosevski V, Hesske L, Fontana A, Magnenat L, Suter T, Becher B. RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol. 2011;12(6):560-567. https://doi.org/10.1038/ni.2027
Markowicz S, Engleman EG. Granulocyte-macrophage colony-stimulating factor promotes differentiation and survival of human peripheralblood dendritic cells in vitro. J Clin Invest. 1990;85(3):955-961.
El-Behi M, Ciric B, Dai H, Yan Y, Cullimore M, Safavi F, Zhang GX, Dittel BN, Rostami A. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat Immunol. 2011;12(6):568-575. https://doi.org/10.1038/ni.2031
Ponomarev ED, Shriver LP, Maresz K, Pedras-Vasconcelos J, Verthelyi D, Dittel BN. GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. J Immunol. 2007;178(1):39-48.
Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA. 2002;99(1):351-358.
Watanabe N, Wang YH, Lee HK, Ito T, Wang YH, Cao W, Liu YJ. Hassall’s corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature. 2005;436(7054):1181-1185.
Lüssi F, Zipp F, Witsch E. Dendritic cells as therapeutic targets in neuroinflammation. Cell Mol Life Sci. 2016;73(13):2425-2450.
Walker LS, Abbas AK. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat Rev Immunol. 2002;2(1):11-19.
Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, Bhardwaj N. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med. 1998;188(7):1359-1368.
Awasthi A, Carrier Y, Peron JP, Bettelli E, Kamanaka M, Flavell RA, Kuchroo VK, Oukka M, Weiner HL. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. Nat Immunol. 2007;8(12):1380-1389.
Pot C, Apetoh L, Kuchroo VK. Type 1 regulatory T cells (Tr1) in autoimmunity. Semin Immunol. 2011;23(3):202-208. https://doi.org/10.1016/j.smim.2011.07.005
Sie C, Korn T. Dendritic cells in central nervous system autoimmunity. Semin Immunopathol. 2017;39(2):99-111. https://doi.org/10.1007/s00281-016-0608-7
Patten SB, Marrie RA, Carta MG. Depression in multiple sclerosis. Int Rev Psychiatry. 2017;29(5):463-472. https://doi.org/10.1080/09540261.2017.1322555
Shubert DS, Foliart RH. Increased depression in multiple sclerosis patients. A metaanalysis. Psychosomatic. 1993;34:124-130.
Kraus C, Castrén E, Kasper S, Lanzenberger R. Serotonin and neuroplasticity — Links between molecular, functional and structural pathophysiology in depression. Neurosci Biobehav Rev. 2017;77:317-326. https://doi.org/10.1016/j.neubiorev.2017.03.007
Jeon SW, Kim YK. Neuroinflammation and cytokine abnormality in major depression: Cause or consequence in that illness? World J Psychiatry. 2016;6(3):283-293. https://doi.org/10.5498/wjp.v6.i3.283
Felger JC. Role of Inflammation in Depression and Treatment Implications. Handb Exp Pharmacol. 2018. https://doi.org/10.1007/164_2018_166
Beurel E, Lowell JA. Th17 cells in depression. Brain Behav Immun. 2018;69:28-34. https://doi.org/10.1016/j.bbi.2017.08.001
Jha MK, Minhajuddin A, Gadad BS, Greer TL, Mayes TL, Trivedi MH. Interleukin 17 selectively predicts better outcomes with bupropion-SSRI combination: Novel T cell biomarker for antidepressant medication selection. Brain Behav Immun. 2017;66:103-110. https://doi.org/10.1016/j.bbi.2017.07.005
Shajib MS, Khan WI. The role of serotonin and its receptors in activation of immune responses and inflammation. Acta Physiol (Oxf). 2015;213(3):561-574. https://doi.org/10.1111/apha.12430
Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M. Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol. 2001;21(2):199-206.
Zhang Y, Zhen H, Yao W, Bian F, Mao X, Yang X, Jin S. Antidepressant drug, desipramine, alleviates allergic rhinitis by regulating Treg and Th17 cells. Int J Immunopathol Pharmacol. 2013;26(1):107-115.
Stefulj J, Cicin-Sain L, Schauenstein K, Jernej B. Serotonin and immune response: effect of the amine on in vitro proliferation of rat lymphocytes. Neuroimmunomodulation. 2001;9(2):103-108.
Dehmel AR Stettner M, Kremer D, Kieseier BC, Hartung HP, Hofstetter HH. Citalopram suppresses thymocyte cytokine production. J Neuroimmunol. 2013;262(1-2):46-52. https://doi.org/10.1016/j.jneuroim.2013.06.006
Idzko M, Panther E, Stratz C. The serotoninergic receptors of human dendritic cells: identification and coupling to cytokine release. J Immunol. 2004;172:6011-6019.
Katoh N, Soga F, Nara T, Tamagawa-Mineoka R, Nin M, Kotani H, Masuda K, Kishimoto S. Effect of serotonin on the differentiation of human monocytes into dendritic cells. Clin Exp Immunol. 2006;146(2):354-361.
Müller T, Dürk T, Blumenthal B, Grimm M, Cicko S, Panther E, Sorichter S, Herouy Y, Di Virgilio F, Ferrari D, Norgauer J, Idzko M. 5-Hydroxytryptamine Modulates Migration, Cytokine and Chemokine Release and T-Cell Priming Capacity of Dendritic Cells in vitro and in vivo. PLoS One. 2009; 4(7):e6453. https://doi.org/10.1371/journal.pone.0006453
Szabo A, Gogolak P, Koncz G, Foldvari Z, Pazmandi K, Miltner N, Poliska S, Bacsi A, Djurovic S, Rajnavolgyi E. Immunomodulatory capacity of the serotonin receptor 5-HT2B in a subset of human dendritic cells. Sci Rep. 2018;8(1):1765. https://doi.org/10.1038/s41598-018-20173-y
Branco-de-Almeida LS, Kajiya M, Cardoso CR, Silva MJ, Ohta K, Rosalen PL, Franco GC, Han X, Taubman MA, Kawai T. Selective serotonin reuptake inhibitors attenuate the antigen presentation from dendritic cells to effector T lymphocytes. FEMS Immunol Med Microbiol. 2011;62(3):283-294. https://doi.org/10.1111/j.1574-695X.2011.00816.x
Gershon MD, Tack J. The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 2007;132:397-414.
Mawe GM, Hoffman JM. Serotonin signalling in the gut—functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol. 2013;10:473-486.
Reigstad CS, Salmonson CE, Rainey JF 3rd, Szurszewski JH, Linden DR, Sonnenburg JL, Farrugia G, Kashyap PC. Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. FASEB J. 2015;29(4):1395-1403. https://doi.org/10.1096/fj.14-259598
Asano Y, Hiramoto T, Nishino R, Aiba Y, Kimura T, Yoshihara K, Koga Y, Sudo N. Critical role of gut microbiota inthe production of biologically active, free catecholamine in the gut lumen of mice. Am J Physiol Gastrointest Liver Physiol. 2012;303(11):1288-1295. https://doi.org/10.1152/ajpgi.00341.2012
Mittal R, Debs LH, Patel AP, Nguyen D, Patel K, O’Connor G, Grati M, Mittal J, Yan D, Eshraghi AA, Deo SK, Daunert S, Liu XZ. Neurotransmitters: The Critical Modulators Regulating Gut-Brain Axis. J Cell Physiol. 2017;232(9):2359-2372. https://doi.org/10.1002/jcp.25518
Dinan TG, Stanton C, Cryan JF. Psychobiotics: a novel class of psychotropic. Biol Psychiatry. 2013;74:720-726.
Yano JM, Yu K, Donaldson GP, Shastri GG, Ann P, Ma L, Nagler CR, Ismagilov RF, Mazmanian SK, Hsiao EY. Indigenous Bacteria from the Gut Microbiota Regulate Host Serotonin Biosynthesis. Cell. 2015;161(2):264-276. https://doi.org/10.1016/j.cell.2015.02.047
O’Mahony SM, Clarke G, Borre YE, Dinan TG, Cryan JF. Serotonin, tryptophan metabolism and the brain-gut-microbiome axis. Behav Brain Res. 2015;277:32-48.
Savignac HM, Couch Y, Stratford M, Bannerman DM, Tzortzis G, Anthony DC, Burnet PWJ. Prebiotic administration normalizes lipopolysaccharide (LPS) induced anxiety and cortical 5-HT2A receptor and IL1-β levels in male mice. Brain Behav Immun. 2016;52:120-131. https://doi.org/10.1016/j.bbi.2015.10.007
Clarke G, Grenham S, Scully P, Fitzgerald P, Moloney RD, Shanahan F, Dinan TG, Cryan JF. The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner. Mol Psychiatry. 2012;18(10):666-673. https://doi.org/10.1038/mp.2012.77
Jenkins TA, Nguyen JC, Polglaze KE, Bertrand PP. Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis. Nutrients. 2016;8(1):E56. https://doi.org/10.3390/nu8010056
Oleskin AV, Rogovsky VS. The role of biogenic amines in the interaction of the microbiota, the nervous and immune systems of the host organism. Bulletin of Restorative Medicine. 2017;1:41-51 (In Russ.)
Foster JA, Rinaman L, Cryan JF. Stress & the gut-brain axis: Regulation by the microbiome. Neurobiology of Stress. 2017.
Scott CF Jr, Cashman N, Spitler LE. Experimental allergic encephalitis; treatment with drugs which alter CNS serotonin levels. J Immunopharmacol. 1982-1983;4(3):153-162.
Freire-Garabal M, Núñez MJ, Balboa J, García-Vallejo LA, Argibay S, Rodrigo E, Rey-Méndez M. Administration of the 5-hydroxytryptamine(1A) receptor antagonist WAY100635 suppresses acute experimental allergic encephalomyelitis in Lewis rats. Neurosci Lett. 2003;342(1-2):33-36.
Hofstetter HH, Mössner R, Lesch KP, Linker RA, Toyka KV, Gold R. Absence of reuptake of serotonin influences susceptibility to clinical autoimmune disease and neuroantigen-specific interferon-gamma production in mouse EAE. Clin Exp Immunol. 2005;142(1):39-44.
Vollmar P, Nessler S, Kalluri SR, Hartung HP, Hemmer B. The antidepressant venlafaxine ameliorates murine experimental autoimmune encephalomyelitis by suppression of pro-inflammatory cytokines. Int J Neuropsychopharmacol. 2009;12(4):525-536. https://doi.org/10.1017/S1461145708009425
Taler M, Gil-Ad I, Korob I, Weizman A The immunomodulatory effect of the antidepressant sertraline in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis. Neuroimmunomodulation. 2011;18(2):117-122. https://doi.org/10.1159/000321634
Musgrave T, Benson C, Wong G, Browne I, Tenorio G, Rauw G, Baker GB, Kerr BJ. The MAO inhibitor phenelzine improves functional outcomes in mice with experimental autoimmune encephalomyelitis (EAE). Brain Behav Immun. 2011;25(8):1677-1688. https://doi.org/10.1016/j.bbi.2011.06.011
Benson CA, Wong G, Tenorio G, Baker GB, Kerr BJ. The MAO inhibitor phenelzine can improve functional outcomes in mice with established clinical signs in experimental autoimmune encephalomyelitis (EAE). Behav Brain Res. 2013;252:302-311. https://doi.org/10.1016/j.bbr.2013.06.019
Yuan XQ, Qiu G, Liu XJ, Liu S, Wu Y, Wang X, Lu T. Fluoxetine promotes remission in acute experimental autoimmune encephalomyelitis in rats. Neuroimmunomodulation. 2012;19(4):201-208. https://doi.org/10.1159/000334095
Bhat R, Mahapatra S, Axtell RC, Steinman L. Amelioration of ongoing experimental autoimmune encephalomyelitis with fluoxetine. J Neuroimmunol. 2017;313:77-81. https://doi.org/10.1016/j.jneuroim.2017.10.012
Sacramento PM, Monteiro C, Dias ASO, Kasahara TM, Ferreira TB, Hygino J, Wing AC, Andrade RM, Rueda F, Sales MC, Vasconcelos CC, Bento CAM. Serotonin decreases the production of Th1/Th17 cytokines and elevates the frequency of regulatory CD4+ T-cell subsets in multiple sclerosis patients. Eur J Immunol. 2018;48(8):1376-1388. https://doi.org/10.1002/eji.201847525
Alvarenga-Filho H, Sacramento PM, Ferreira TB, Hygino J, Abreu JE, Carvalho SR, Wing AC, Alvarenga RM, Bento CA. Combined exercise training reduces fatigue and modulates the cytokine profile of T-cells from multiple sclerosis patients in response to neuromediators. J Neuroimmunol. 2016;293:91-99. https://doi.org/10.1016/j.jneuroim.2016.02.014
Mostert JP, Sijens PE, Oudkerk M, De Keyser J. Fluoxetine increases cerebral white matter NAA/Cr ratio in patients with multiple sclerosis. Neurosci Lett. 2006;402(1-2):22-24.
Mostert JP, Admiraal-Behloul F, Hoogduin JM, Luyendijk J, Heersema DJ, van Buchem MA, De Keyser J. Effects of fluoxetine on disease activity in relapsing multiple sclerosis: a double-blind, placebo-controlled, exploratory study. J Neurol Neurosurg Psychiatry. 2008;79(9):1027-1031. https://doi.org/10.1136/jnnp.2007.139345
Connick P, De Angelis F, Parker RA, Plantone D, Doshi A, John N, Stutters J, MacManus D, Prados Carrasco F, Barkhof F, Ourselin S, Braisher M, Ross M, Cranswick G, Pavitt SH, Giovannoni G, Gandini Wheeler-Kingshott CA, Hawkins C, Sharrack B, Bastow R, Weir CJ, Stallard N, Chandran S, Chataway J; UK Multiple Sclerosis Society Clinical Trials Network. Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. BMJ Open. 2018;8(8):e021944. https://doi.org/10.1136/bmjopen-2018-021944